Dan Nandan is the Founder and CEO of Staffingly, Inc., based in Piscataway, New Jersey. With 25+ years in IT consulting and a decade leading healthcare BPO operations across India, Latin America, and Pakistan, his team now serves 800+ U.S. healthcare providers across medical, dental, pharmacy, and post-acute care verticals.
2026 Compliance Verified: HIPAA, SOC 2 Type II, ISO 27001, HITRUST-aligned workflows.
Featured in Computerworld →
State of Illinois. Registered Professional Nurse
Bincy Shiiju Kuriakose is a U.S.-licensed Registered Nurse (MSN, RN), NCLEX-RN certified, with expertise in hospital nursing, telehealth, and nursing education. She reviews every publication for medical accuracy, YMYL compliance, and evidence-based clinical context.
What Is Wegovy medication eligibility?
Wegovy is semaglutide 2.4 mg, a GLP-1 receptor agonist FDA-approved for chronic weight management. It works by reducing appetite and slowing gastric emptying, leading to sustained weight loss when combined with diet and exercise. Adults qualify at BMI 30 or greater, or BMI 27 or greater with at least one weight-related comorbidity. Pediatric patients aged 12 and older qualify at BMI at or above the 95th percentile for their age and sex with body weight exceeding 60 kg.
FDA Eligibility Criteria for Wegovy (BMI and Comorbidity Breakdown)
Understanding the exact eligibility thresholds prevents submissions for patients who do not meet criteria and ensures proper documentation for those who do.
- BMI >= 30: Qualifies for Wegovy without any additional conditions. Document the BMI with the exact date of measurement. A BMI recorded as “36.9” without a date is a top denial trigger because payers cannot verify it was current at the time of prescription.
- BMI 27-29.9: Must have at least one weight-related comorbidity documented with the correct ICD-10 code: hypertension (I10), type 2 diabetes (E11.9), dyslipidemia (E78.x), obstructive sleep apnea (G47.33), or cardiovascular disease. The comorbidity must be actively coded in the patient’s problem list, not merely mentioned in a progress note. Payers cross-reference the PA against the coded diagnosis list.
- Pediatric (12+): BMI at or above the 95th percentile for age and sex, with body weight exceeding 60 kg. Pediatric eligibility requires age-appropriate BMI percentile documentation, not adult BMI thresholds. Many practices incorrectly apply adult criteria to adolescent patients.
- Most denials for eligible patients happen for two preventable reasons: the BMI was documented without a date of measurement, or comorbidities were listed in clinical notes but not properly coded with ICD-10 in the patient’s active problem list.
Insurance Eligibility by Payer Type (Commercial vs. Medicare vs. Medicaid)
Coverage depends entirely on the insurance type, and the rules are different enough that practices need separate workflows for each.
- Commercial plans: Most major commercial insurers cover Wegovy with PA. According to IFEBP 2024, 34% of employers now include GLP-1s for weight loss in their benefit packages, up from less than 20% two years ago. Step therapy may be required before approval, typically involving a trial of phentermine-topiramate or orlistat. The NovoCare savings card from Novo Nordisk reduces eligible commercially insured patients’ copay to $0-$25 per month. This program does not apply to government insurance patients. The key variable is whether the employer’s specific plan document covers anti-obesity medications. The insurer’s standard formulary may list Wegovy, but the employer may have excluded the entire drug class.
- Medicare Part D: Currently covers Wegovy ONLY for the cardiovascular indication in patients with established CVD and obesity or overweight. Weight loss alone is not a covered indication under traditional Part D. The GLP-1 Bridge program starts July 1, 2026 as a CMS demonstration covering Wegovy for Part D beneficiaries with BMI 35 or greater, or BMI 27 or greater with clinical criteria. The copay is $50 per month. The Bridge program does not count toward the Part D deductible or the $2,100 out-of-pocket cap. Low-Income Subsidy does not apply.
- Medicaid: FL, TX, and OH all exclude Wegovy for obesity indications. Only 13 state Medicaid programs nationwide cover GLP-1s for weight loss. In Medicaid exclusion states, the only covered use is for type 2 diabetes management under a different indication. This is why the first question at scheduling must be about insurance type.
Save 40-70% with dedicated Eligibility specialists
Book a 15-minute call. We will map your current eligibility verification workflow, denial rates, and staff hours against what a dedicated team typically delivers in the first 30 days.
State-by-State Eligibility: Florida, Texas, and Ohio
Florida: Medicaid explicitly excludes weight-loss GLP-1s including Wegovy. There is no PA pathway for Wegovy under Florida Medicaid for obesity. Florida Blue commercial plans cover Wegovy with PA for qualified patients on employer-sponsored plans. For Medicaid patients, screen at intake and redirect immediately to cash-pay options, the NovoCare savings program, or manufacturer patient assistance. Do not invest staff time in PA preparation for a plan that will not approve it.
Texas: Medicaid excludes obesity GLP-1s statewide. BCBS TX and UHC TX commercial plans cover Wegovy with PA under most employer plans. A 2025 legislative push to expand Medicaid GLP-1 coverage stalled without passage. Texas has a high proportion of self-funded employer plans, and many large employers in the energy and technology sectors have specifically excluded weight loss medications from their benefit designs. Verify at the plan level, not the insurer level.
Ohio: Medicaid limits GLP-1 coverage to type 2 diabetes only. Weight management is not a covered indication under any Ohio Medicaid managed care plan. Anthem BCBS OH and CareSource commercial plans cover Wegovy with PA plus step therapy requirements. Coverage criteria vary by employer plan.
In all three states, the most efficient screening question at first patient contact is: “Are you on Medicaid or commercial insurance?” This single question saves 20-30 minutes of wasted screening per Medicaid patient and prevents frustration on both sides when a plan exclusion surfaces late in the process.
Pre-Visit Eligibility Screening Checklist (Before the Patient Walks In)
This checklist should be completed before the patient arrives for their appointment. Running it after the visit wastes the provider’s clinical time and delays PA submission by at least one appointment cycle.
- Confirm insurance type (commercial, Medicare, or Medicaid). If Medicaid in FL, TX, or OH, the patient is ineligible for Wegovy for weight loss. Redirect immediately.
- Check formulary status via Availity, the PBM’s portal, or a direct phone call to the pharmacy benefit number. Confirm that Wegovy is listed on the patient’s specific plan, not just on the insurer’s standard formulary.
- Identify PA requirements and step therapy rules. Know what the payer requires before the provider writes the prescription. If 6 months of lifestyle modification documentation is needed, the clinical team needs that information now.
- Review the patient’s documented BMI history in the EMR. Confirm that a current BMI with a date of measurement exists in the chart. If the most recent BMI is older than 90 days, plan to record a new one at the visit.
- Confirm no concurrent GLP-1 prescriptions. Wegovy cannot be used with Ozempic, Rybelsus, or other GLP-1 receptor agonists. Check the medication list for conflicts.
- Flag contraindications including personal or family history of medullary thyroid carcinoma, MEN 2 syndrome, pregnancy, or breastfeeding.
This entire checklist is completable by a trained virtual medical assistant in under 5 minutes per patient, well before the appointment starts.
Documentation Requirements for Wegovy Eligibility
Complete documentation is the difference between a first-pass approval and a denial that delays treatment by weeks. Every element in the following list must be present in the chart and referenced in the PA submission.
BMI must include the exact measurement with a specific date, formatted as “BMI 36.9 as of 04/15/2026.” A BMI recorded without a date is the single most common documentation gap that triggers denial. ICD-10 codes must include the obesity diagnosis (E66.01 for morbid obesity due to excess calories, E66.09 for other obesity) plus any comorbidity codes that establish eligibility at BMI 27-29.9, such as I10 for hypertension or E11.9 for type 2 diabetes.
Payers require 3 to 6 months of documented prior weight-loss attempts, including dietary counseling, exercise programs, or behavioral modification, with dates and outcomes. Prior medication trials must list each medication tried, the duration of use, the reason for discontinuation, and whether the patient experienced adverse effects or insufficient response. Confirm in the chart that the patient is not currently on another GLP-1 receptor agonist, as concurrent use is a contraindication. Include provider attestation of medical necessity explaining why Wegovy is clinically appropriate for this specific patient. Lab work should include A1c, lipid panel, and thyroid function tests if clinically relevant. Incomplete documentation is the number one PA denial reason for anti-obesity medications across all payers.
What Happens When Eligibility Is Denied (And Why You Should Always Appeal)
The data on GLP-1 appeals tells a clear story: 60% of first appeals succeed, but 88% of eligible patients never appeal (KFF/OIG 2023). That gap represents thousands of patients who qualified for Wegovy, were denied on a technicality, and never received treatment because no one filed the appeal.
The most common denial reasons are all fixable. BMI not documented with a date means the payer could not confirm the measurement was current. The fix is resubmitting with the dated BMI. Missing comorbidity codes means the ICD-10 diagnoses were in the clinical notes but not coded on the active problem list. The fix is adding the codes and resubmitting. Step therapy not completed means the payer required a trial of an alternative medication first, and the documentation of that trial was either missing or insufficient. The fix is providing detailed records of the prior trial including dates, doses, duration, and reason for discontinuation.
For plans that truly exclude weight-loss medications from their formulary, no appeal will succeed. In those cases, redirect the patient immediately to the NovoCare savings card from Novo Nordisk (which can reduce commercially insured patients’ cost to $0-$25 per month), manufacturer patient assistance programs, or cash-pay options through specialty pharmacies. The key is determining whether the denial is a documentation issue (fixable through appeal) or a plan exclusion (not fixable) and acting accordingly within 72 hours.
Medicare GLP-1 Bridge Program: What Changes in July 2026
CMS demonstration: July 1 to December 31, 2026. Covers Wegovy and Zepbound for Medicare Part D beneficiaries. BMI >= 35 alone, or >= 27 with clinical criteria. $50/month (does NOT count toward Part D deductible or $2,100 OOP cap). Low-Income Subsidy does NOT apply. BALANCE Model launches January 2027 for full Part D coverage. Practices should update screening workflows now to include Bridge criteria.
How Staffingly Handles Wegovy Patient Eligibility Screening
Staffingly VMAs handle the full screening workflow: pre-visit formulary checks, BMI and comorbidity documentation review, payer-specific criteria matching, PA-readiness assessment, patient communication on coverage status. 800+ providers. $399/week (volume discounts to $299/week). 70% savings. 99.2% clean claim rate. 48-72 hour go-live. 50+ EHR platforms. SOC 2 Type II, ISO 27001, HIPAA compliant.
The honest patient conversation most Wegovy articles skip: Even if you win eligibility, the patient may not be able to afford continuation. Manufacturer savings cards drop the first few months to $25, then reset. Patients who cannot sustain $400-$600/month out of pocket will discontinue at month 4, and they regain weight fast. Screening eligibility is step one. Screening affordability and coverage durability is step two, and it is the step most practices skip until the patient calls to cancel. Build that conversation into the PA approval workflow, not after.
What Did We Learn?
Wegovy eligibility requires confirming FDA criteria, matching payer-specific rules, documenting comorbidities with ICD-10 codes, and knowing which state Medicaid programs cover it (FL, TX, OH do not). The Medicare GLP-1 Bridge launching July 2026 changes the eligibility picture for millions. Practices that screen eligibility before the clinical visit save time, reduce denials, and get patients on therapy faster.
FAQs (8)
Q1: What BMI do you need to qualify for Wegovy? Adults with BMI >= 30 qualify. BMI 27-29.9 qualifies with at least one weight-related condition (T2D, hypertension, dyslipidemia, OSA). Adolescents 12+ must be at or above the 95th BMI percentile and weigh more than 60 kg.
Q2: Does Medicaid cover Wegovy in Florida, Texas, or Ohio? No. FL, TX, and OH Medicaid do NOT cover Wegovy for weight loss. They only cover GLP-1s for Type 2 diabetes. Only 13 state Medicaid programs nationally cover GLP-1s for obesity.
Q3: Will Medicare cover Wegovy in 2026? Starting July 1, 2026, the Medicare GLP-1 Bridge covers Wegovy for Part D beneficiaries with BMI >= 35 or BMI >= 27 with clinical criteria. $50/month copay. Full Part D coverage under BALANCE Model begins January 2027.
Q4: What comorbidities qualify at BMI 27? Hypertension, Type 2 diabetes, dyslipidemia, obstructive sleep apnea, and cardiovascular disease. Must be documented with ICD-10 codes in the EMR.
Q5: What documentation is required? BMI with exact date, comorbidity diagnoses with ICD-10 codes, 3-6 months prior weight-loss attempts, prior medications tried, confirmation not on another GLP-1, and provider attestation.
Q6: How long does eligibility and PA approval take? Electronic PAs via CoverMyMeds or payer portals: 24-72 hours with complete documentation. Faxed forms: 5-10+ business days. Most plans respond within 3-7 business days.
Q7: What if Wegovy is denied? Appeal immediately. 60% of first appeals succeed, but 88% of patients never try. Prepare letter of medical necessity, address the specific denial reason, submit within 72 hours.
Q8: Can adolescents get Wegovy covered? FDA-approved for ages 12-17 with BMI >= 95th percentile and weight > 60 kg. Many plans, especially Medicaid, do not cover pediatric use. Verify age-specific coverage with the payer.
Ready to Cut Prior Auth and Eligibility Headaches?
Staffingly helps practices like yours get paid faster with a 99.2% clean-claim rate, 65-70% cost savings, and 48-72 hour go-live. SOC 2 Type II, and ISO 27001 certified. HIPAA compliant. MGMA Corporate Member.
- Start a 2-Week Free Trial and see results before you commit.
- Call us: (800) 489-5877